Halma plc, a global group of life-saving technology companies, has acquired French firm Lamidey Noury Medical for around £42 million.
Founded in 1947 and headquartered close to Paris, Lamidey Noury manufactures advanced electrosurgical and associated energy devices which are used in minimally invasive urology, gynaecology and general surgery.
Its products are sold to healthcare providers in over 60 countries.
The cash consideration for Lamidey Noury is €50m (approximately £42m), on a cash- and debt-free basis, to be funded from Halma’s existing facilities.
Lamidey Noury’s unaudited revenue for the 12 months to October 2024 was approximately £11.4m, with an EBIT margin above the upper end of Halma’s target range of 19-23%. It will operate as a standalone company within Halma’s healthcare sector, led by its current management team.
“Lamidey Noury is an exciting acquisition which will bring new minimally invasive surgical product capabilities to our healthcare sector,” said Marc Ronchetti, group CEO of Halma.
“Its advanced products improve patient outcomes and the efficiency of healthcare providers in treating the increasing incidence of urological and gynaecological disease. It is adjacent to our existing presence in diagnosis and biopsy devices for these diseases through Rovers Medical Devices and IZI Medical.
“We are delighted to welcome Lamidey Noury to Halma and look forward to supporting its development as it continues to scale its business globally.”
Guillaume Noury, president of Lamidey Noury, said: “Joining Halma is an exciting opportunity for us. Leveraging Halma’s expertise, resources, and global reach will accelerate our growth and innovation.
“We are confident in our ability to continue delivering high-quality surgical tools to our customers worldwide, while providing new opportunities for our employees and stakeholders.
“Together, we will continue improving patient outcomes and driving excellence in healthcare.”
‘The sea plastic on David Attenborough? It came from your recycling bin’